Evidence map›Paper›PMID 41916283›Full record

ArticleNeuron2026

Large-scale CSF and plasma proteomics reveal immune, synaptic, and extracellular matrix disruptions across neurodegenerative diseases.

Muhammad Ali, Jigyasha Timsina, Ying Xu, Yike Chen, Katherine Gong, Daniel Western, Gyujin Heo, Menghan Liu, John Budde, Cyril Pottier and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuron, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Muhammad AliDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Jigyasha TimsinaDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Ying XuDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Yike ChenDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Katherine GongDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Daniel WesternDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Gyujin HeoDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Menghan LiuDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
John BuddeDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Cyril PottierDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
John C MorrisDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
David M HoltzmanDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Raquel PuertaACE Alzheimer Center Barcelona, Barcelona, Spain.
Amanda CanoACE Alzheimer Center Barcelona, Barcelona, Spain.
Merce BoadaACE Alzheimer Center Barcelona, Barcelona, Spain.
Maria V FernandezACE Alzheimer Center Barcelona, Barcelona, Spain.
Agustin RuizACE Alzheimer Center Barcelona, Barcelona, Spain.
Miquel AguilarFundació Docència i Recerca Mútua de Terrassa, Terrassa, Barcelona, Spain.
Ignacio AlvarezFundació Docència i Recerca Mútua de Terrassa, Terrassa, Barcelona, Spain.
Pau PastorFundació Docència i Recerca Mútua de Terrassa, Terrassa, Barcelona, Spain.
Joel S PerlmutterDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Meghan C CampbellDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Paul T KotzbauerDepartment of Neurology, Washington University, St. Louis, MO 63110, USA.
Hamilton Se-Hwee OhDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Edward N WilsonWu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305, USA.
Yann Le GuenWu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305, USA.
Knight Alzheimer Disease Research Center (Knight-ADRC)
Alzheimer Disease Neuroimaging Initiative (ADNI)
Fundació ACE Alzheimer Center Barcelona (FACE)
Barcelona-1
Stanford Alzheimer Disease Research Center (Stanford-ADRC)
Global Neurodegeneration Proteomics Consortium (GNPC)
Rawan TarawnehDepartment of Neurology, Saint Louis University, St. Louis, MO 63110, USA.
Tony Wyss-CorayWu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305, USA.
Yun Ju SungDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA.
Laura IbanezDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA; Department of Neurology, Washington University, St. Louis, MO 63110, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University, St. Louis, MO 63110, USA; Department of Neurology, Washington University, St. Louis, MO 63110, USA. Electronic address: cruchagac@wustl.edu.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS, Suzanne Elizabeth Schindler · 1985 to 2026
$69.5M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Dissecting the Genomic Etiology of non-Mendelian Early-Onset Alzheimer Disease and Related PhenotypesR01AG064614 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BEECHAM, GARY WAYNE, CRUCHAGA, CARLOS · 2019 to 2023
$11.5M
Identification and Characterization of Cell-Specific Transposable Elements Implicated on Alzheimer Disease and Healthy AgingR01AG078964 · NIA · WASHINGTON UNIVERSITY · PI Carlos Cruchaga, Bess Frost · 2022 to 2026
$9.0M
Genetic Architecture of Alzheimer’s disease ProteinopathiesR01AG064877 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CRUCHAGA, CARLOS, KAMBOH, M. ILYAS · 2021 to 2024
$8.4M
INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASER01NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2011 to 2021
$8.2M
Protein Aggregation and Neurotransmitter Deficits in Parkinson DiseaseR01NS097799 · NINDS · WASHINGTON UNIVERSITY · PI PAUL T KOTZBAUER · 2016 to 2026
$5.8M
Parkinson Disease Clinical Subtypes: Validation, Clinical Utility, and Biological CorrelatesR01NS097437 · NINDS · WASHINGTON UNIVERSITY · PI MEGHAN C CAMPBELL · 2017 to 2026
$4.1M
USING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITSRF1AG053303 · NIA · WASHINGTON UNIVERSITY · PI CLIMER, SHARLEE, CRUCHAGA, CARLOS · 2016 to 2020
$4.0M
GENETIC MODIFIERS OF CEREBROSPINAL FLUID TREM2 IN ALZHEIMER'S DISEASERF1AG058501 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, PICCIO, LAURA · 2018 to 2018
$3.5M
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG044546NIA NIH HHS R01 AG058501NIA NIH HHS R01 AG064614NIA NIH HHS R01 AG064877NIA NIH HHS R01 AG071706NIA NIH HHS R01 AG078964NIA NIH HHS RF1 AG053303NIA NIH HHS RF1 AG058501NIA NIH HHS RF1 AG071706NIA NIH HHS RF1 AG074007NIA NIH HHS RF1 AG083744NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG058922NINDS NIH HHS R01 NS075321NINDS NIH HHS R01 NS097437NINDS NIH HHS R01 NS097799NINDS NIH HHS RF1 NS075321
6 · The paper itself

Abstract

Neurodegenerative diseases (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), share overlapping clinical and pathological features. We analyzed cerebrospinal fluid (CSF) and plasma proteomes from 2,705 and 3,009 samples, respectively, across these NDs, identifying disease-specific and shared molecular signatures. CSF showed more disease-associated proteins than plasma, with AD and DLB exhibiting the strongest cross-tissue similarity. Pathway analyses revealed shared dysregulation of immune-related processes in CSF and plasma across the NDs, as well as disease-specific impairment of glycosylation and apoptotic pathways in AD; ATF4 and PERK signaling in PD; fibroblast growth factor receptor (FGFR) and interleukin signaling in DLB; and glycoprotein hormones disruption in FTD. We developed disease-specific predictive models showing high accuracy (area under the curve [AUC]: 0.81-0.95 in CSF and 0.80-0.89 in plasma). These findings reveal distinct and convergent mechanisms across NDs, highlighting potential biomarkers and pathways for diagnostic and therapeutic strategies in neurodegeneration.

Indexed as

Extracellular MatrixNeurodegenerative DiseasesProteomeSynapsesAlzheimer DiseaseBiomarkersFemaleHumansLewy Body DiseaseMaleParkinson DiseaseProteomicsBiomarkersProteomeAlzheimer's diseaseCSFdementia with Lewy bodiesfrontotemporal dementianeurodegenerationOlinkParkinson's diseaseplasmaproteomicsSomaScan

Identifiers

PMID41916283
PMCPMC13052424

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.